The evolving landscape of primary headache therapy

Migraine serves as a success story in translational neurology, with an increased understanding of disease mechanisms 1 and recent therapeutic advances for both acute and preventive treatment 2,3. Despite this success, migraine remains one of the leading causes of disability globally 4, and with the recent discontinuation of lasmiditan 5, a first in class serotonin 5-HT1F receptor agonist 6,7, the therapeutic tool kit, especially for patients with cardiovascular risk, has taken a step in the wrong direction.